MicroRNA-21 mediated cross-talk between cardiomyocytes and fibroblasts in patients with atrial fibrillation.
atrial fibrillation
fibrosis
low-voltage area
miR-21
mocetinostat
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
09
2022
accepted:
01
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Atrial fibrosis represents a major hallmark in disease progression of atrial fibrillation (AF). We have previously shown that circulating microRNA-21 (miR-21) correlates with the extent of left atrial fibrosis in patients undergoing catheter ablation for AF and can serve as a biomarker to predict ablation success. In this study, we aimed to validate the role of miR-21-5p as a biomarker in a large cohort of AF patients and to investigate its pathophysiological role in atrial remodeling. For the validation cohort, we included 175 patients undergoing catheter ablation for AF. Bipolar voltage maps were obtained, circulating miR-21-5p was measured, and patients were followed-up for 12 months including ECG holter monitoring. AF was simulated by tachyarrhythmic pacing of cultured cardiomyocytes, the culture medium was transferred to fibroblast, and fibrosis pathways were analysed. 73.3% of patients with no/minor LVAs, 51.4% of patients with moderate LVAs and only 18.2% of patients with extensive LVAs were in stable sinus rhythm (SR) 12 months after ablation ( We validated miR-21-5p as a biomarker that reflects the extent of left atrial fibrosis in AF patients. Furthermore, we found that miR-21-5p is released
Sections du résumé
Background
UNASSIGNED
Atrial fibrosis represents a major hallmark in disease progression of atrial fibrillation (AF). We have previously shown that circulating microRNA-21 (miR-21) correlates with the extent of left atrial fibrosis in patients undergoing catheter ablation for AF and can serve as a biomarker to predict ablation success. In this study, we aimed to validate the role of miR-21-5p as a biomarker in a large cohort of AF patients and to investigate its pathophysiological role in atrial remodeling.
Methods
UNASSIGNED
For the validation cohort, we included 175 patients undergoing catheter ablation for AF. Bipolar voltage maps were obtained, circulating miR-21-5p was measured, and patients were followed-up for 12 months including ECG holter monitoring. AF was simulated by tachyarrhythmic pacing of cultured cardiomyocytes, the culture medium was transferred to fibroblast, and fibrosis pathways were analysed.
Results
UNASSIGNED
73.3% of patients with no/minor LVAs, 51.4% of patients with moderate LVAs and only 18.2% of patients with extensive LVAs were in stable sinus rhythm (SR) 12 months after ablation (
Conclusion
UNASSIGNED
We validated miR-21-5p as a biomarker that reflects the extent of left atrial fibrosis in AF patients. Furthermore, we found that miR-21-5p is released
Identifiants
pubmed: 36873400
doi: 10.3389/fcvm.2023.1056134
pmc: PMC9982105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1056134Informations de copyright
Copyright © 2023 Pradhan, Niehues, Neupane, Maleck, Sharif-Yakan, Emrani, Zink, Napp, Marx and Gramlich.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2021 Mar 24;22(7):
pubmed: 33804922
Prim Care Companion CNS Disord. 2013;15(1):
pubmed: 23724342
Cardiovasc Res. 2019 Nov 1;115(13):1850-1860
pubmed: 30596969
N Engl J Med. 2021 Jan 28;384(4):305-315
pubmed: 33197159
Circ Res. 2020 Jul 17;127(3):427-447
pubmed: 32673537
Circ Arrhythm Electrophysiol. 2012 Oct;5(5):1027-35
pubmed: 22923342
Circulation. 2014 Jan 21;129(3):346-58
pubmed: 24146251
Heart Fail Rev. 2020 Sep;25(5):731-743
pubmed: 31512150
J Mol Cell Cardiol. 2018 Aug;121:205-211
pubmed: 30040954
Oncotarget. 2017 Apr 25;8(17):28471-28480
pubmed: 28212530
Circ Arrhythm Electrophysiol. 2019 Mar;12(3):e007071
pubmed: 30879335
Cardiovasc Res. 2002 May;54(2):230-46
pubmed: 12062329
Oxid Med Cell Longev. 2019 Apr 17;2019:5703764
pubmed: 31178968
Fibrogenesis Tissue Repair. 2012 Jun 06;5(Suppl 1):S24
pubmed: 23259531
Respir Res. 2013 Sep 24;14:95
pubmed: 24063588
N Engl J Med. 2021 Jan 28;384(4):316-324
pubmed: 33197158
J Cell Mol Med. 2018 Aug;22(8):3816-3824
pubmed: 29808534
Cardiovasc Res. 2009 Apr 1;82(1):21-9
pubmed: 19147652
N Engl J Med. 2015 May 7;372(19):1812-22
pubmed: 25946280
Heart Lung Circ. 2018 Jan;27(1):104-113
pubmed: 28495464
Int J Mol Sci. 2015 May 19;16(5):11482-99
pubmed: 25997003
Eur Heart J. 2013 Sep;34(35):2746-51
pubmed: 23900699
J Cardiovasc Electrophysiol. 2021 Apr;32(4):1147-1160
pubmed: 33682258
Sarcoma. 2019 Aug 27;2019:7608743
pubmed: 31534435
Heart Rhythm. 2015 Jan;12(1):3-10
pubmed: 25257092
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
J Exp Med. 2020 Feb 13;217(3):e20190103
pubmed: 32997468
Heart. 2003 Aug;89(8):939-43
pubmed: 12860883
Circ Arrhythm Electrophysiol. 2018 Jun;11(6):e006242
pubmed: 29848477
J Am Heart Assoc. 2022 Mar 15;11(6):e024521
pubmed: 35261287
Biomed Res Int. 2018 May 29;2018:3694362
pubmed: 30003094
Biochim Biophys Acta Mol Cell Res. 2020 Mar;1867(3):118459
pubmed: 30880147
Lancet Oncol. 2011 Dec;12(13):1222-8
pubmed: 22033282
JAMA. 2014 Feb 5;311(5):498-506
pubmed: 24496537
Cell Death Differ. 2008 Apr;15(4):667-71
pubmed: 18219318
J Cardiovasc Electrophysiol. 2021 Apr;32(4):916-924
pubmed: 33600025
Br J Haematol. 2017 Aug;178(3):434-441
pubmed: 28440559
Cell Physiol Biochem. 2017;42(6):2207-2219
pubmed: 28817807
Circulation. 2013 Apr 9;127(14):1466-75, 1475e1-28
pubmed: 23459615
Eur J Pharmacol. 2016 Jun 15;781:250-7
pubmed: 27089819